Skip to content

Effect of Postural Change on Hemoglobin Level in Patients on the Intensive Care Unit

Effect of Postural Change on Hemoglobin Level in Patients on the Intensive Care Unit

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06438458
Enrollment
24
Registered
2024-06-03
Start date
2024-06-17
Completion date
2024-10-30
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia

Keywords

Blood composition, Circulatory physiology

Brief summary

Monitoring hemoglobin levels (Hb) is important to identify anemia in hospitalized patients. Changes in posture and mobilization efforts, as demonstrated by previous research, can lead to significant shifts in Hb concentrations. This phenomenon has not been studied in ICU patients. This study aims to investigate whether postural changes and mobilisation affect Hb in ICU patients. We hypothesize that significant Hb shifts may occur, potentially leading to misinterpretations of anemia and unnecessary diagnostic and therapeutic workup. Understanding this impact can guide clinical practice and prevent unwarranted interventions.

Detailed description

Rationale: Monitoring hemoglobin levels (Hb) is important to identify anemia in hospitalized patients. Changes in posture and mobilization efforts, as demonstrated by previous research, can lead to significant shifts in Hb concentrations. Low Hb levels due to these shifts are termed 'postural pseudoanemia'. This phenomenon has not been studied in ICU patients. Many factors may affect Hb concentrations in ICU patients, including plasma volume shifts, bleeding, repeated phlebotomies, hemolysis, bone marrow suppression and functional iron deficiency. When this leads to significant anemia, patients may be treated with red blood cell transfusions. However, blood transfusions have been associated with adverse reactions and should only be performed for appropriate indications. If postural pseudoanemia occurs in ICU patients this could lead to patient harm through inadvertent investigations and red blood cell transfusions. The occurrence of postural pseudoanemia in ICU patients may differ from previous studies because ICU patients are more frequently immobilized for more prolonged periods. This study aims to investigate whether postural changes affect Hb in ICU patients. We hypothesize that significant Hb shifts may occur, potentially leading to misinterpretations of anemia and unnecessary diagnostic and therapeutic workup. Understanding this impact can guide clinical practice and prevent unwarranted interventions. Objective: Main objective: To assess Hb levels in ICU patients upon a change in posture from supine to upright and following mobilization to a chair. Secondary objectives: To seek correlations between hemoglobin shifts and changes in serum albumin concentrations upon a change in posture from supine to sitting and following mobilization to a chair. To seek correlations between hemoglobin shifts and changes in serum uric acid concentrations upon a change in posture from supine to sitting and following mobilization to a chair. To seek correlations between hemoglobin shifts and levels of CRP and ESR upon a change in posture from supine to sitting and following mobilization to a chair. To compare hemoglobin concentrations following \> 6 hours in supine position at 24 hours with pre-intervention levels for patients remaining in the ICU. Any other changes seen in the lab measurements or vital parameters upon a change in posture? Study design: Prospective uncontrolled interventional study. Study population: Patients \> 18 years old, admitted to the intensive care unit. Intervention: All patients will undergo a change in posture from supine to upright, followed by mobilization to a chair. Main study parameters/endpoints: Relative percentage change in Hb.

Interventions

PROCEDUREPostural change from supine to sitting

Patients go from supine to sitting position in bed (passive)

PROCEDUREMobilization to a chair

Patients go from the bed to sitting in a chair (active)

Sponsors

Deventer Ziekenhuis
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Blood samples are taken before and after the interventions

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age over 18 years, of any gender and ethnic background * Admitted to the intensive care unit * Able to give informed consent * Patients with an arterial line as part of their treatment plan. * Patients able to remain seated in chair for at least 30 minutes * Patients able to remain supine overnight for at least 6 hours

Exclusion criteria

* Delirium or inability to give informed consent * Inability to understand written information in Dutch * Patients on artificial ventilation * Orotracheally intubated patients (spontaneous breathing through a tracheostomy cannula is allowed) * Patients treated with noradrenaline \> 0.05 ug/kg/min * Patients treated with argipressin * Patients who received a blood transfusion within 24 hours before measurements * Patients who received \> 3 L of fluids within 24 hours before measurements * Patients who received \> 500 ml of iv fluids within 4 hours of measurements * Severe restlessness or inability to remain supine for 6 hours before initial blood sampling * Patients being treated with diuretics * Patients admitted with: * Decompensated right heart failure * Pulmonary hypertension * Pulmonary embolism * Active bleeding or risk of \>100 ml blood loss * Hematological disorder/malignancy

Design outcomes

Primary

MeasureTime frameDescription
Hemoglobin3 hoursHemoglobin concentration

Secondary

MeasureTime frameDescription
Albumin3 hoursAlbumin concentration

Other

MeasureTime frameDescription
Uric acid3 hoursUric acid concentration

Countries

Netherlands

Contacts

Primary ContactAlfred L van Steveninck, M.D., Ph.D.
f.steveninckvan@dz.nl+31570535346
Backup ContactHuub LA van den Oever, M.D.
h.vandenoever@dz.nl+31570535346

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026